P2-315: A Novel Biotherapy for the Treatment of Alzheimer's Disease

Jin Yu,Sebastiano Gattoni-Celli,Hong Zhu,Mark S. Kindy

DOI: https://doi.org/10.1016/j.jalz.2008.05.1392

2008-01-01

Alzheimer s & Dementia

Abstract:Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the brain, which is by far the most prevalent form of dementia in adults over 65 years old. Amyloid β peptide (Aβ)-containing senile plaques are one of the neuropathological hallmarks of AD. The gradual accumulation of aggregated Aβ peptide initiates a complex multistep cascade, which include gliosis, inflammatory changes, oxidative stress, tangle formation (microtubule changes), neuritic/synaptic changes, and transmitter loss that finally lead to dementia. One of the strategies used to increase the clearance of Aβ peptide from the brain involves immunization with Aβ peptide 1–42 (Aβ1–42). However, clinical trials of active immunization were halted when patients in the study developed meningocephalitis. We have recently reported that semi-allogeneic somatic cell hybrids generated by the fusion of EL-4 T lymphoma cells (H-2b) and BALB/c-derived renal adenocarcinoma RAG cells (H-2d) can protect C57BL/6 mice (H-2b) challenged with a tumorigenic dose of EL-4 cells. The results of our studies are entirely consistent with the concept that the semi-allogeneic vaccine (made of RAG X EL-4 cell hybrids) induce a potent T cell-mediated (Th-1) response, that instructs T lymphocytes to kill autologous (EL-4) tumor cells. We have subsequently modified RAG X EL-4 cell hybrids to specifically target Aβ1–42. Ten-week-old female C57BL/6 APP transgenic mice (APPswe, PSEN1dE9) were treated with a single dose of modified RAG X EL-4 somatic cell hybrids, injected intraperitoneally (i.p.). At six months of age, all mice were sacrificed and their brains were fixed and sectioned to count the amyloid plaques. We observed that the brains of APP mice, treated with a single dose of the semi-allogeneic cell hybrids formulated with Aβ1–42, showed less numerous and smaller plaques compared to the brains of APP mice treated with Aβ1–42 in PBS or with unmodified RAG X EL-4 cell hybrids in PBS. The results of these preliminary animal studies led us to hypothesize that a T cell-mediated (Th-1) immune response targeting the Aβ1–42 will help clear this peptide from the brain, resulting in enhanced cognition, without the risk of adverse events such as meningocephalitis.